[
A new study was published in New England Journal of Medicine (NEJM) raises serious questions over the efficacy of Pfizer's antiviral drug Paxlovid, which was previously authorized for emergency use to treat mild to moderate COVID-19 cases.
Paxlovid received emergency use authorization in December 2021 as the first home treatment for COVID-19 in the United States. It was promoted as a cost-effective and efficient method to deal with initial COVID-19 infections.
Pfizer reported in its press release that paxlovid reduced the risk of COVID-19-related hospitalization or death by 88%.
Gateway Pundit has been covering the ineffectiveness and adverse reactions associated with Pfizer's antiviral drug.
Scientific documentation about post-paxalvid relapse is available since the fall of 2022. Pfizer's application to the FDA for emergency use authorization of paxalovid said that in the placebo-controlled clinical trial — which included 2,246 participants — “many subjects appeared to rebound after starting treatment,” NBC reported. SARS-CoV-2 RNA levels peak around day 10 or 14.
Following this report, Pfizer issued a statement acknowledging that it had failed to reduce the risk of confirmed and symptomatic COVID-19 infection in adults living with someone exposed to the virus.
Albert Bourla, Chairman and Chief Executive Officer of Pfizer, said, “We have built a broad and ambitious clinical development program for PAXLOVID, which is aimed at helping combat COVID-19 in a much broader population of patients. “
“Although we are disappointed with the outcome of this particular study, these results do not impact the strong efficacy and safety data we have obtained from our earlier trials to treat COVID-19 patients at high risk of developing severe disease. “We are pleased to see the increasing global use of PAXLOVID in that population,” Bourla said.
It may be recalled that Paxlovid was associated with cases of rapid rebound infection. Notably, several high-profile figures such as Dr. Anthony Fauci, Joe Biden, Jill Biden, and former CDC Director Dr. Rochelle Walensky reported experiencing a resurgence of COVID-19 symptoms after treatment with the drug. Has given.
Most of these individuals received two initial doses of the vaccine and two booster shots, with Dr. Walensky receiving an additional third booster.
Gateway Pundit also reported that paxolovid can cause serious or life-threatening effects if it is taken with other common medications, including some anticoagulants, anti-depressants and cholesterol-lowering drugs that are widely prescribed across the US. Are used from. Warning from the Food and Drug Administration (FDA).
When Joe Biden tested positive for COVID and started Paxlovid in July, Joe Biden's doctor said he prescribed Paxlovid to treat Biden's COVID infection because of Biden's atrial fibrillation and high cholesterol. Had stopped heart medicines. Atrial fibrillation can cause stroke and is treated by blood-thinning medications to reduce the risk of blood clots causing stroke.
“His apixaban (Eliquis) and rosuvastatin (Crestor) are being maintained during paclovid treatment and for several days after his last dose. During this time, it is advisable to include low-dose aspirin as an alternative type of blood thinner,” said Dr. Kevin O'Connor, Biden's personal physician.
In addition to potentially dangerous drug combinations, the agency does not recommend that people with kidney or liver disease take the new drug because it may also lead to complications.
Now, The Hill's Amber Duke and Jessica Burbank highlight the discrepancy between the drug's high cost and its actual effectiveness, based on a new NEJM study.
The Biden regime's $12 billion investment in Paxlovid, against the backdrop of Pfizer selling $20 billion worth of the drug before these findings emerged, raises serious questions about the evaluation and promotion of the COVID-19 treatment.
“Paxalovid, once considered a wonder drug to defeat COVID-19, may not be so powerful after all. A study published in the New England Journal of Medicine on Wednesday shows that the antiviral drug may be effective in both fully vaccinated and unvaccinated people who have at least one risk factor for severe COVID. Does little or nothing for. “It didn't help shorten the duration of symptoms,” Duke said.
“Adults who had confirmed COVID-19 with onset of symptoms in the past five days were randomly assigned to take paxlovid or placebo every 12 hours for five days. Patients who were fully vaccinated against Covid and patients who had never been vaccinated against Covid were eligible to participate in the study. Now, it is shocking that the drug that costs $1,300 for five courses is not actually relieving COVID symptoms in a randomized controlled trial. It seems like a huge amount of money to pay for something that hasn't been proven to work,” Burbank said.
Duke responded, “This is part of a larger trend of the medical community, and especially Big Pharma, both taking advantage when it comes to COVID-19 and repeatedly peddling the American public.” Sell bills. Of course, they routinely scoff at medical treatments like ivermectin or hydroxychloroquine, saying they were fish tank cleaner or horse dewormer, even though these drugs have been used for human treatment in varying doses for decades. Has been, and basically they wanted the government to put it in. All its money is in promoting vaccine development among these big pharmaceutical companies. They didn't want people to take potentially effective treatments because they would destroy people's desire to develop a vaccine. And then they had their own medical treatments like Paxlivit, which doesn't even work, and made $20 billion on it. It was such a total racket from start to finish.”